Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
BioDiem Ltd - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'BioDiem Ltd - Product Pipeline Review - 2015', provides an overview of the BioDiem Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of BioDiem Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of BioDiem Ltd including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of BioDiem Ltd's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the BioDiem Ltd's pipeline products Reasons To Buy - Evaluate BioDiem Ltd's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of BioDiem Ltd in its therapy areas of focus - Identify new drug targets and therapeutic classes in the BioDiem Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of BioDiem Ltd and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioDiem Ltd - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of BioDiem Ltd and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 BioDiem Ltd Snapshot 5 BioDiem Ltd Overview 5 Key Information 5 Key Facts 5 BioDiem Ltd - Research and Development Overview 6 Key Therapeutic Areas 6 BioDiem Ltd - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 BioDiem Ltd - Pipeline Products Glance 11 BioDiem Ltd - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 BioDiem Ltd - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 BioDiem Ltd - Drug Profiles 15 influenza vaccine 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 BDM-I 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 dengue fever vaccine 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 hepatitis B vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 hepatitis D vaccine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 murray river encephalitis vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 tuberculosis vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vaccine to Target EBV for Nasopharyngeal Carcinoma 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 West Nile virus vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BioDiem Ltd - Pipeline Analysis 24 BioDiem Ltd - Pipeline Products by Target 24 BioDiem Ltd - Pipeline Products by Route of Administration 25 BioDiem Ltd - Pipeline Products by Molecule Type 26 BioDiem Ltd - Recent Pipeline Updates 27 BioDiem Ltd - Company Statement 29 BioDiem Ltd - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
BioDiem Ltd, Key Information 5 BioDiem Ltd, Key Facts 5 BioDiem Ltd - Pipeline by Indication, 2015 8 BioDiem Ltd - Pipeline by Stage of Development, 2015 9 BioDiem Ltd - Monotherapy Products in Pipeline, 2015 10 BioDiem Ltd - Phase II, 2015 11 BioDiem Ltd - Phase I, 2015 12 BioDiem Ltd - Preclinical, 2015 13 BioDiem Ltd - Discovery, 2015 14 BioDiem Ltd - Pipeline by Target, 2015 24 BioDiem Ltd - Pipeline by Route of Administration, 2015 25 BioDiem Ltd - Pipeline by Molecule Type, 2015 26 BioDiem Ltd - Recent Pipeline Updates, 2015 27 BioDiem Ltd, Subsidiaries 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.